Grape King Bio Ltd (TW:1707) — Market Cap & Net Worth
Market Cap & Net Worth: Grape King Bio Ltd (1707)
Grape King Bio Ltd (TW:1707) has a market capitalization of $407.44 Million (NT$12.93 Billion) as of September 19, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #13428 globally and #528 in its home market, demonstrating a -4.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Grape King Bio Ltd's stock price NT$87.30 by its total outstanding shares 148137000 (148.14 Million). Also see total assets of Grape King Bio Ltd for a full breakdown of the balance sheet.
Grape King Bio Ltd Market Cap History: 2015 to 2026
Grape King Bio Ltd's market capitalization history from 2015 to 2026. Data shows change from $675.94 Million to $407.44 Million (-4.43% CAGR). Also see cash efficiency ratio of Grape King Bio Ltd for how efficiently the company converts equity into cash flow.
Grape King Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Grape King Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Grape King Bio Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.06x
Grape King Bio Ltd's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.48x
Grape King Bio Ltd's market cap is 0.48 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $709.08 Million | $9.19 Billion | $1.30 Billion | 0.08x | 0.55x |
| 2017 | $815.20 Million | $9.39 Billion | $1.35 Billion | 0.09x | 0.60x |
| 2018 | $769.03 Million | $9.18 Billion | $1.30 Billion | 0.08x | 0.59x |
| 2019 | $811.16 Million | $9.24 Billion | $1.94 Billion | 0.09x | 0.42x |
| 2020 | $763.43 Million | $9.17 Billion | $1.90 Billion | 0.08x | 0.40x |
| 2021 | $715.00 Million | $9.80 Billion | $1.95 Billion | 0.07x | 0.37x |
| 2022 | $784.08 Million | $10.39 Billion | $2.17 Billion | 0.08x | 0.36x |
| 2023 | $728.07 Million | $10.64 Billion | $1.45 Billion | 0.07x | 0.50x |
| 2024 | $697.74 Million | $11.16 Billion | $1.45 Billion | 0.06x | 0.48x |
| 2025 | $590.39 Million | $10.25 Billion | $1.22 Billion | 0.06x | 0.48x |
Competitor Companies of 1707 by Market Capitalization
Companies near Grape King Bio Ltd in the global market cap rankings as of September 19, 2026. Review tangible equity quality of Grape King Bio Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Grape King Bio Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Grape King Bio Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Grape King Bio Ltd's market cap moved from $675.94 Million to $ 407.44 Million, with a yearly change of -4.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$407.44 Million | -30.99% |
| 2025 | NT$590.39 Million | -15.38% |
| 2024 | NT$697.74 Million | -4.17% |
| 2023 | NT$728.07 Million | -7.14% |
| 2022 | NT$784.08 Million | +9.66% |
| 2021 | NT$715.00 Million | -6.34% |
| 2020 | NT$763.43 Million | -5.88% |
| 2019 | NT$811.16 Million | +5.48% |
| 2018 | NT$769.03 Million | -5.66% |
| 2017 | NT$815.20 Million | +14.96% |
| 2016 | NT$709.08 Million | +4.90% |
| 2015 | NT$675.94 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Grape King Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $407.44 Million USD |
| MoneyControl | $407.44 Million USD |
| MarketWatch | $407.44 Million USD |
| marketcap.company | $407.44 Million USD |
| Reuters | $407.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; a… Read more